References
1. Broeckx, G. and P. Pauwels, Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res, 2018. 7(5): p. 537-542.
2. Štrbac, D. and V. Dolžan, Novel and Future Treatment Options in Mesothelioma: A Systematic Review. Int J Mol Sci, 2022. 23(4).
3. Yan, T.D., L. Welch, D. Black, and P.H. Sugarbaker, A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol, 2007. 18(5): p. 827-34.
4. Boffetta, P., Epidemiology of peritoneal mesothelioma: a review. Ann Oncol, 2007. 18(6): p. 985-90.
5. Helm, J.H., J.T. Miura, J.A. Glenn, R.K. Marcus, G. Larrieux, T.T. Jayakrishnan, et al., Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol, 2015. 22(5): p. 1686-93.
6. Vermersch, S., A. Arnaud, D. Orbach, N. Andre, C. Berger, V. Kepenekian, et al., Multicystic and diffuse malignant peritoneal mesothelioma in children. Pediatr Blood Cancer, 2020. 67(6): p. e28286.
7. Brigand, C., O. Monneuse, F. Mohamed, A.C. Sayag-Beaujard, S. Isaac, F.N. Gilly, et al., Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol, 2006. 13(3): p. 405-12.
8. Ihemelandu, C., L. Bijelic, and P.H. Sugarbaker, Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol, 2015. 22(5): p. 1680-5.
9. Hommell-Fontaine, J., S. Isaac, G. Passot, E. Decullier, A. Traverse-Glehen, E. Cotte, et al., Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol, 2013. 20(12): p. 3892-8.
10. Kitai, T., The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. Surg Today, 2021. 51(7): p. 1085-1098.
11. Baas, P., A. Scherpereel, A.K. Nowak, N. Fujimoto, S. Peters, A.S. Tsao, et al., First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, 2021. 397(10272): p. 375-386.
12. Hussaini, S., R. Chehade, R.G. Boldt, J. Raphael, P. Blanchette, S. Maleki Vareki, et al., Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev, 2021. 92: p. 102134.
13. Sise, M.E., H. Seethapathy, and K.L. Reynolds, Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist, 2019. 24(6): p. 735-742.